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Abstract
The glycocalyx is a carbohydrate-rich layer that lines the luminal side of the vascular endothelium. Its soluble
components exist in a dynamic equilibrium with the bloodstream and play an important role in maintaining
endothelial layer integrity. However, the glycocalyx can be easily damaged and is extremely vulnerable to insults
from a variety of sources, including inflammation, trauma, haemorrhagic shock, hypovolemia and ischaemia-
reperfusion. Damage to the glycocalyx commonly precedes further damage to the vascular endothelium. Preclinical
research has identified a number of different factors capable of protecting or regenerating the glycocalyx. Initial
investigations suggest that plasma may convey protective and regenerative effects. However, it remains unclear
which exact components or properties of plasma are responsible for this protective effect. Studies have reported
protective effects for several plasma proteins individually, including antithrombin, orosomucoid and albumin; the
latter of which may be of particular interest, due to the high levels of albumin present in plasma. A further
possibility is that plasma is simply a better intravascular volume expander than other resuscitation fluids. It has also
been proposed that the protective effects are mediated indirectly via plasma resuscitation-induced changes in gene
expression. Further work is needed to determine the importance of specific plasma proteins or other factors for
glycocalyx protection, particularly in a clinical setting.
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Background
The endothelial glycocalyx is a carbohydrate-rich layer
that lines the vascular endothelium. The presence of a
protein layer on the endothelium was first proposed by
Danielli in 1940 [1] and was visualised using electron
microscopy in 1966 [2]. Initial investigations of the gly-
cocalyx were hampered as previous staining and fixing
techniques destroyed this fragile structure [3]. However,
contemporary methods preserve the glycocalyx and have
enabled more detailed examination of the structure and
physiology of this layer [4].
The glycocalyx is connected to the endothelium via
several cell-bound core molecules, mainly proteoglycans
and glycoproteins (Fig. 1). On the luminal surface, the
glycocalyx is formed by soluble plasma components, ei-
ther linked to each other directly or via soluble proteo-
glycans, glycosaminoglycans and sialoproteins [5, 6]. A
dynamic equilibrium exists between the layer of soluble
components and the bloodstream, where the blood flow
constantly affects both the composition and the thick-
ness of the glycocalyx [5]. For example, Ueda and col-
leagues reported that the glycocalyx in bovine aortic
endothelial cells increase in thickness as sheer stress in-
creases up to 3.0 Pa [7]. Additionally, the glycocalyx
contains a large volume of non-circulating plasma; es-
timated at 1–1.7 L [8, 9], and has a net negative
charge that affects its interaction with plasma constit-
uents, platelets and red blood cells, thereby counter-
acting microvascular thrombosis and maintaining
rheology [4, 10, 11].
Situated between the endothelium and the blood-
stream, the glycocalyx serves several functions including
limiting access of particular molecules to the
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endothelium, influencing blood cell–vessel wall interac-
tions and acting as a mechanotransducer (Table 1) [5,
10, 12–20]. For example, the glycocalyx is semiperme-
able to certain macromolecules such as plasma proteins
(e.g. albumin) but cannot be penetrated by red blood
cells or large molecules such as dextran (>70 kD) [16].
Conformational changes in glycocalyx structure also lead
to release of nitric oxide, affecting vasomotor tone and
tissue perfusion [18]. Furthermore, as the glycocalyx
binds plasma proteins it creates a high intravascular
oncotic pressure at the endothelial surface; The net
outward movement of fluid is therefore opposed by
this inward-directed oncotic pressure, according to
the Starling equation and the paracellular permeability
model [21].
Other soluble components that bind to the luminal
portions of the glycocalyx are unbound hyaluronic acid
molecules, superoxide dismutase, antithrombin III, pro-
tein C and cell adhesion molecules [18]. Due to the
many functions of the glycocalyx, it is perhaps unsur-
prising that any disruption or damage to this layer con-
tributes towards numerous vascular pathologies [5].
Literature review
The aim of this paper was to review and summarise the
clinical findings relating to the biological functions of
the glycocalyx layer and its damage and regeneration or
protection. As a number of publications were found to
evaluate the restorative effects of fresh frozen plasma
(FFP), this review goes on to explore if a specific compo-
nent of FFP is considered to be responsible for these ef-
fects. A non-systematic literature search was conducted
using MEDLINE (PubMed) with the objective of iden-
tifying English language articles published up to 14th
January 2016, which provided information regarding the
endothelial glycocalyx and its functions. A broad search
was performed using the term “glycocalyx” and a total of
2458 articles were retrieved. Following review of the title
and abstract, 2318 articles were discarded as they were
not relevant e.g. non-English language, not related to
damage or protection/regeneration. Reviews and articles
that described general roles and structure of the glycoca-
lyx were retained for background information. Finally,
additional articles of interest that were identified during
development of this review were also included.
Fig. 1 Schematic representation of the glycocalyx and its constituents. Syndecan and glypican are membrane-bound proteoglycans which carry
chondroitin sulfate and heparan sulfate side chains. Syndecans are anchored to the plasma membrane via a single-span transmembrane protein
and may therefore act as receptors. Glypicans are attached to the cell surface via a glycosylphosphatidylinositol (GPI) anchor. The glycocalyx is also
comprised of secreted proteoglycans, such as perlecan, together with secreted glycosaminoglycans, such as hyaluronan. Note that this figure is
not drawn to scale
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Damage to the glycocalyx
The glycocalyx is surprisingly delicate and sustains in-
jury quite easily. Damage can range from deterioration
through to fundamental destruction of the glycocalyx.
Studies in isolated organs, animal models and clinical
studies have investigated how the glycocalyx is damaged
and this research is described here.
In vitro and isolated organ models
Studies in isolated organs and cells demonstrate that dis-
ruption and shedding of the glycocalyx is associated with
a number of different molecules and stress factors. Topical
and intrascrotal application of TNF-α to the hamster cre-
master microcirculation resulted in damage to the glyco-
calyx, as observed by increased access of fluorescein
isothiocyanate (FITC)-labeled dextrans 70 and 580 to the
space bounded by the apical glycocalyx in arterioles, capil-
laries and venules [22]. Atrial natriuretic peptide was also
shown to be associated with shedding of the glycocalyx,
assessed by increased release of syndecan-1 in the
coronary vascular bed in a guinea pig heart model [23].
Furthermore, abnormal blood shear stress was also shown
to increase glycocalyx shedding in cultured human vascu-
lar umbilical endothelial cells [24].
Shedding of the glycocalyx components appears to be
a regulated process influenced by several factors. A study
in SVEC4-10 endothelial cells demonstrated increased
glycocalyx shedding in response to a range of stimuli in-
cluding the proteases thrombin and plasmin, as well as
the protein kinase C modulator phorbol 12-myristate
12-acetate and epidermal growth factor, suggesting shed-
ding is also modulated by tyrosine kinases and G
protein-coupled receptors (GPCRs), in addition to prote-
ases [25].
Animal models
In rodent models, disruption and shedding of the glyco-
calyx components, like syndecan-1 and heparan sulfate,
has been demonstrated in response to hyperglycaemia
[26], haemorrhagic shock [27, 28], inflammation and
ischaemia-reperfusion injury [29]. Increased shedding
and decreased colloid osmotic pressure (COP) could be
markers of inflammation [28], but other factors may be
equally responsible for the observed effects on both gly-
cocalyx shedding and endothelial permeability.
In a porcine model, the combination of traumatic
brain injury and haemorrhagic shock resulted in glycoca-
lyx shedding within 15 min after injury [30].
Clinical studies
Shedding of the glycocalyx in humans has been demon-
strated in response to hypovolaemia [31] and has also
been observed in patients undergoing aortic or cardiac
bypass surgery [12, 32]. In patients undergoing aortic by-
pass surgery, it was demonstrated that heparan sulfates
shed from the glycocalyx can directly activate leukocytes
and platelets which, in turn, release heparanases that
can also degrade heparan sulfate chains, leading to a vi-
cious cycle that can make it challenging to confirm the
initial cause of the glycocalyx damage [12]. Thus, in line
with data obtained from experiments in isolated organs
and animal models, disruption of the glycocalyx in
humans also leads to the release of specific components
into the circulation. In a clinical setting, these compo-
nents may be valuable in assessing the severity of the
damage and clinical outcomes. Circulating levels of
syndecan-1 and heparan sulfate are proportionally re-
lated to the degree of glycocalyx damage. For example,
in trauma patients, a high level of syndecan-1 is associ-
ated with coagulopathy and increased mortality [33] and,
in patients with septic shock, increased levels of glycos-
aminoglycans have been shown to correlate with mortality
[34]. Rahbar and colleagues [35] observed shedding of
four primary components of the glycocalyx (syndecan-1,
Table 1 Functions of the glycocalyx
Function Reference
Forms the interface between
the vessel wall and the bloodstream
Reitsma et al. 2007 [5]
Alphonsus and Rodseth 2014 [10]
Maintains the colloid osmotic
gradient of the vascular barrier
Rehm et al. 2007 [12]
Acts as a barrier to:
vascular exchange of
water and solutes
Reitsma et al. 2007 [5]
leukocyte–endothelium adhesion Henry and Duling 1999 [13]
Lipowsky et al. 2011 [14]
Constantinescu et al. 2003 [15]
Becker et al. 2015 [19]
Acts as a sieve for
plasma proteins
Vink and Duling 2000 [16]
Lipowsky et al. 2011 [14]
Provides binding sites for
everal molecules, including:
antithrombin III Alphonsus and Rodseth 2014 [10]
tissue factor pathway inhibitors Reitsma et al. 2007 [5]
lipoprotein lipase Kolářová et al. 2014 [18]




Acts as a shear stress sensor and
regulator of mechanotransduction
Reitsma et al. 2007 [5]
Florian et al. 2003 [17]
Yen et al. 2014 [20]
Becker et al. 2015 [19]
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heparan sulfate, hyaluronic acid and chondroitin sulfate)
in severely injured trauma patients and noted that
syndecan-1, heparan sulfate and endothelial cell perme-
ability were significantly higher in patients with reduced
plasma COP; thrombin generation was also impaired in
these patients. The loss of thrombin generation may be
explained by endogenous heparinisation as suggested by
Ostrowski and Johansson [36]. However, further studies
are warranted before drawing definitive conclusions re-
garding any implied causality between glycocalyx degrad-
ation and decreased COP. In a study by Koning and
colleagues, patients undergoing cardiac surgery with car-
diopulmonary bypass (CPB) experienced acute glycocalyx
injury in contrast to off-pump surgery [32]. Glycocalyx
shedding is also linked to endothelial cell damage, often
measured as high levels of soluble thrombomodulin
(sTM) [36]. sTM is an endothelial cell transmembrane
glycoprotein that is only released upon direct endothelial
disruption. In sepsis, sTM better predicted risk of multiple
organ failure compared with syndecan-1, and only sTM
predicted death [37]. Additionally, syndecan-1 measured
during emergency department admission has been found
to be useful for assessing the risk of developing acute kid-
ney injury and in-hospital mortality in patients with acute
decompensated heart failure [38]. Based on these findings,
further investigations of whether specific markers of gly-
cocalyx integrity may be of value in guiding treatment and
clinical decision-making may be warranted.
Protection and regeneration of the glycocalyx
Given its importance in various physiological functions
and the delicate nature of this layer, protection of the
glycocalyx may prove a promising target in critical care
settings as well as in the treatment of chronic vascular
disease. In fact, several studies have investigated whether
the glycocalyx can be protected or if damage can be
repaired. Some of the agents that have been studied are
detailed below (Table 2).
In vitro and isolated organ models
In a study of rat fat-pad endothelial cells, glycocalyx shed-
ding induced by removal of albumin from the culture
medium, was rescued by application of sphingosine-1-
phosphate, demonstrating that sphingosine-1-phosphate
GPCRs are also involved in preserving glycocalyx integrity
[39]. Additionally, the same group found that the role of
sphingosine-1-phosphate on glycocalyx recovery is medi-
ated by the phosphoinositide 3-kinase pathway [40].
Using isolated perfused guinea pig hearts, Chappell and
colleagues demonstrated that the glycocalyx could be pro-
tected against ischaemia-reperfusion injury or inflamma-
tory degradation initiated by TNF-α by pre-treatment
with hydrocortisone or antithrombin [41–44]. Exogenous
administration of nitric oxide during reperfusion was also
shown to protect the glycocalyx in isolated guinea pig
hearts [45]. However, nitric oxide had no preventive effect
on coronary leak or oedema if the glycocalyx was
destroyed enzymatically beforehand. A combination of
hyaluronic acid and chondroitin sulphate, two glycocalyx
abundant glycosaminoglycans, partially regenerated the
capillary glycocalyx damaged by hyaluronidase in ham-
sters; treatment with either molecule separately had no ef-
fect [13].
In a guinea pig heart model of transplantation-induced
ischaemia/reperfusion glycocalyx damage, infusion of
5 % albumin or 6 % hydroxethyl starch, a natural and an
artificial colloid, led to decreased fluid extravasation [8,
46]. Augmenting the traditional preservation solution
with albumin was also reported to protect the glycocalyx
in this model [47]. Based on these findings, the re-
searchers suggested that maintaining a physiological al-
bumin blood concentration before the onset of a
surgical procedure may be adequate to protect vascular
integrity [46]. The effect of FFP was investigated in an in
vitro model of endothelial injury and found that FFP, but
not lactated Ringer’s, preserved syndecan-1 and main-
tained endothelial junction integrity [48]. The mechan-
ism by which FFP mitigates syndecan-1 shedding is
unknown. The authors hypothesise that FFP may inhibit
or neutralise sheddases (a diverse group of proteases)
and/or that FFP mobilises intracellular stores of pre-
formed syndecans.
Animal models
In the postcapillary venules of the rat mesentery, glycoca-
lyx shedding, induced by the chemoattractant f-Met-Leu-
Phe, was significantly reduced by inhibition of matrix me-
talloproteinases using the zinc chelator ilomastat, as well
as subantimicrobial concentrations of doxycycline [49].
During endotoxaemia, activated protein C prevented ca-
pillary perfusion deficit in lipopolysaccharide-treated rats
Table 2 Treatments linked with protection of the glycocalyx
Treatment Reference
Hydrocortisone Chappell et al. 2007, 2009b, 2010 [41, 43, 44]
Antithrombin Chappell et al. 2009a, 2009b, 2010 [42–44]
Protein C Marechal et al. 2008 [50]
Nitric oxide Bruegger et al. 2008 [45]
Hyaluronic acid and
chondroitin sulphate
Henry and Duling 1999 [13]
Sulodexide Broekhuizen et al. 2010 [54]
Lidoflazine Flameng et al. 1983 [55]
Albumin Jacob et al. 2006, 2009 [46, 47]
Hydroxethyl starch Rehm et al. 2004; Jacob et al. 2006 [8, 46]
N-acetylcysteine Nieuwdorp et al. 2006 [9]
Metformin Eskens et al. 2013 [51]
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leading to preservation of the glycocalyx [50]. In a mouse
model of non-insulin dependent diabetes mellitus, treat-
ment with metformin was associated with an improve-
ment in the barrier properties of the glycocalyx [51].
Using a haemorrhagic shock model in rats, Kozar and
colleagues investigated the effect of plasma resuscitation
on the glycocalyx [27]. Early signs of glycocalyx restor-
ation were demonstrated within 2 h of plasma resuscita-
tion, compared with no repair with lactated Ringer’s
solution. Furthermore, expression of lung syndecan-1
mRNA was enhanced by plasma resuscitation, suggest-
ing that plasma restores the backbone of the glycocalyx
[27]. The authors concluded that the protective effects
of plasma may be due, in part, to its ability to restore
the glycocalyx and preserve syndecan-1 after haemor-
rhagic shock.
In a haemorrhagic shock model in microvessels of the
cremaster muscle, the effects of FFP, a 6 % hydroxyethyl
starch solution and lactated Ringer’s solution were com-
pared for their ability to repair the endothelial glycocalyx
structure, promote volume expansion, increase blood flow
and prevent coagulopathy. After resuscitation, glycocalyx
thickness was reduced by approximately 70 % in rats in
the haemorrhage only (no resuscitation), 6 % hydroxyethyl
starch or lactated Ringer’s groups whereas the FFP-treated
rats recovered glycocalyx thickness 1 h post-resuscitation
[28]. Plasma syndecan-1 levels were also restored to base-
line levels following resuscitation with FFP compared with
the 6 % hydroxyethyl starch and lactated Ringer’s groups
which were 50 % higher than sham and FFP. Furthermore,
resuscitation with FFP improved coagulation and blood
flow and restored pH and base excess to baseline levels.
The authors state that the efficacy of FFP may be related
to reconstitution of the glycocalyx structure, volume ex-
pansion and renewal of overall protein levels.
In a mouse model of haemorrhagic shock and trauma,
treatment with FFP and spray-dried plasma (SDP) were
compared with lactated Ringer’s solution [52]. Both FFP
and SDP reduced permeability and inflammation and
modulated vascular integrity. Mean arterial pressures and
base excess were also corrected to levels observed in
sham-treated mice by both FFP and SDP.
In a haemorrhagic shock model, rats were resuscitated
with either fresh whole blood (FWB), 1:1 packed RBC
(pRBC)/lactated Ringer’s, 1:1 washed pRBC/lactated
Ringer’s or lactated Ringer’s alone [53]. Resuscitation with
FWB and pRBCs improved glycocalyx thickness compared
with washed pRBCs, suggesting that the protective effects
on the endothelium may be associated with the presence
of residual plasma proteins.
Clinical studies
In clinical trials of patients with type 2 diabetes, sulodex-
ide administration for 2 months increased glycocalyx
thickness; likely as a result of enhanced precursor abun-
dance for glycosaminoglycan synthesis [54]. In an older
study, pre-treatment with lidoflazine (a calcium channel
blocker) preserved the glycocalyx in a dose-dependent
manner in patients undergoing multiple aorta-coronary
bypass grafting [55]. Furthermore, controlling diet-
induced hyperlipidaemia and hypercholesterolaemia
could also protect the glycocalyx [4].
As mentioned earlier, the glycocalyx can be damaged
in a variety of clinical situations, including cardiac sur-
gery and haemorrhagic shock. However, in patients
undergoing cardiac surgery with CPB, the use of pulsa-
tile flow was associated with recovery of glycocalyx di-
mensions within four hours of the initial injury caused
by the onset of extracorporeal circulation; this recovery
was absent after nonpulsatile CPB [32].
Haywood-Watson and colleagues investigated whether
FFP would restore the glycocalyx and reduce syndecan-1
shedding in severely injured patients in haemorrhagic
shock [48]. In line with data from pre-clinical experi-
ments, plasma syndecan-1 levels were markedly elevated
in these patients and correlated with specific inflamma-
tory cytokines (IFN- , fractalkine and IL-1β were nega-
tively correlated while IL-10 was positively correlated),
all of which play an important role in maintaining the
endothelial integrity [48]. Plasma syndecan-1 levels were
found to decrease following resuscitation but were still
elevated compared to normal patients, suggesting partial
restoration of the glycocalyx took place following admin-
istration of FFP. Furthermore, it has been shown that
plasma-based resuscitation of trauma patients in haem-
orrhagic shock leads to a decrease in mortality [56, 57].
Which factors mediate the restorative effects of plasma?
The above studies indicate that FFP has beneficial effects
on the glycocalyx. These benefits have been shown to di-
minish once FFP has been thawed and then stored be-
fore use [58]. In vitro studies have shown that FFP
decrease the permeability of pulmonary endothelial cells.
This effect was diminished when FFP was thawed and
stored for 5 days compared with freshly thawed FFP;
FFP stored for 10 days had no protective effect and actu-
ally exacerbated permeability. Additionally, the thrombin
generating capacity of FFP was also found to diminish
between Days 0 and 5 of storage, and in vivo studies
demonstrated that Day 0 FFP was able to restore and
maintain blood pressure at baseline levels whereas Day 5
could not [58].
The question that remains to be answered is what spe-
cific constituents or properties of the plasma are mediat-
ing its protective effect. Several factors may be involved
in mediating the restorative effects of plasma on the gly-
cocalyx. One possibility is that plasma is simply a better
volume expander compared to crystalloid resuscitation
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fluids and therefore more effectively counteracts ischemia-
induced changes of the glycocalyx. Another possibility is
that alterations in gene expression and protein synthesis in
response to plasma resuscitation play a vital role. Finally, it
is possible that one or more plasma proteins are directly
responsible for the protective effects. For instance, plasma
albumin constitutes the largest pool of thiols in the circula-
tion and effectively reduces oxidative stress due to its
radical-scavenging reduced cysteine and methionine resi-
dues [59]. Protective effects may also be mediated by the
ability of albumin to inhibit platelet activation [60] or its
ability to transport a variety of free fatty acids [61] and hor-
mones [62].
In vitro and isolated organ models
It is likely that specific plasma proteins are involved in
glycocalyx protection and regeneration, and data from
isolated organ models have identified several compounds
capable of either protecting or damaging the glycocalyx.
Protective effects have been reported for antithrombin
III in an isolated guinea pig heart model [42]. Con-
versely, C-reactive protein dose-dependently increased
hyaluronan while decreasing heparan sulfate surface ex-
pression and glycocalyx thickness in human aortic endo-
thelial cells [63]. A recent study by Deng and colleagues
found that immunodepletion of adiponectin from FFP
eliminated its ability to inhibit hypoxia-induced hyper-
permeability in human endothelial cells [64].
Animal models
Adiponectin has been found to be an important compo-
nent of FFP in a mouse model of haemorrhagic shock
[64]. In this study, immunodepletion of adiponectin
from FFP eliminated its effects on improving lung vascu-
lar barrier function in mice after haemorrhagic shock;
however, replenishment with FFP rescued these effects.
In studies where the proposed beneficial effects of FFP
have been demonstrated, plasma volume has not been
measured, and it is not known whether comparable vol-
ume expansion was achieved between the treatment
groups. Comparable volume expansion was the objective
in an in vivo study employing a mouse trauma and
haemorrhagic shock model where FFP and crystalloids
were used at a ratio of 1:3 [65]. FFP was shown to re-
store the glycocalyx and reduce syndecan-1 shedding.
However, since plasma volumes were not measured it is
not known if this effect was due to improved volume ex-
pansion or other properties of plasma [65].
In order to determine whether the protective effects of
plasma are secondary to better volume expansion com-
pared to crystalloids, we recently investigated the effects
of resuscitation with FFP or Ringer’s acetate on plasma
volume expansion and glycocalyx shedding in a rat
model of haemorrhagic shock. The ratio of FFP to
Ringer’s acetate in this study was ≈ 1:4. Even so, FFP
produced a greater plasma volume expansion than
Ringer’s acetate, suggesting that FFP is a better
plasma volume expander than previously thought
[66]. Although we did not discover any evidence of
FFP-mediated reduction in glycocalyx shedding in this
study it should be noted that degradation markers
were only assessed at one time point, exactly two
hours after resuscitation. It is possible that differences
between FFP and other treatments are detectable at
other time points.
Another possibility is that protective effects are me-
diated indirectly, via plasma resuscitation-induced
changes in gene expression. For instance, Potter and
colleagues demonstrated that FFP and SDP, but not
lactated Ringer’s, conveyed endothelial cell protection
and induced a similar pattern of endothelial cell gene
expression in a murine model of haemorrhagic shock
[52]. These data suggest that plasma may control
cell–cell communication and vasoreactivity of the
endothelium, and may therefore serve as a starting
point for elucidating the mechanism of action of
plasma on the glycocalyx.
Clinical studies
Evidence of the protective effects of plasma is not
limited to pre-clinical data. A prospective, observa-
tional study in severely injured patients with haem-
orrhagic shock demonstrated significantly elevated
levels of syndecan-1 (554 ± 93 ng/ml) in injured pa-
tients [48]. Resuscitation with FFP resulted in an ap-
proximately 3-fold decrease in circulating syndecan-1
levels (187 ± 36 ng.ml), although they remained ele-
vated compared to the levels measured in a control
group of healthy plasma donors (27 ± 1 ng/ml).
In a study of non-bleeding, critically ill patients, a
prophylactic dose of FFP was infused prior to an invasive
procedure [67]. FFP transfusion decreased subsequent
levels of syndecan-1 and was associated with an increase in
the von Willebrand factor (vWF)-cleaving metalloprotein-
ase ADAMTS13 and a corresponding decrease in vWF.
Large vWF multimers damage the endothelium and the
authors suggest that ADAMTS13 may have increased the
ability to cleave vWF large multimers present on the
endothelium, potentially stabilising the condition of
the endothelium. Notably, this appears to contradict
results from the animal studies [49] which suggested
that inhibition of metalloproteases with hydroxamate
inhibitors, known to inhibit ADAMTS13 [68], reduce
glycocalyx shedding.
It is worth noting that plasma contains an abundance of
proteins, and it remains unclear to what extent one specific
protein showing benefits in isolation is involved in the pro-
tective effects of plasma in vivo, and by which mechanism.
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Conclusions
The glycocalyx plays a fundamental role in the microcir-
culation and in the initiation and regulation of coagula-
tion and inflammation. Therapeutic strategies aimed at
protecting this delicate layer are poorly understood at
this time. While the various beneficial effects of FFP
have been demonstrated, there is still no information as
to what the mode of action is and if this is due to a par-
ticular constituent of the plasma. Further research is ne-
cessary to understand how FFP and other therapeutic
strategies can benefit protect the glycocalyx and ultim-
ately the patient.
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